Skip to main content

MorphoSys Value Stock - Dividend - Research Selection

MorphoSys

ISIN: DE0006632003, WKN: 663200

Market price date: 29.05.2020
Market price: 116,65 EUR




MorphoSys Fundamental data and company key figures of the share

Annual reports in EUR
Key figures 22-03-2020
Cash flow
Net operating cash flow -80.138.600
Capital Expenditures -3.103.330
Free cash flow -83.241.928
Balance sheet
Total Equity 394.702.000
Liabilities & Shareholders equity 496.439.000
Income statement
Net income -103.014.000
Eps (diluted) -3,260
Diluted shares outstanding 31.599.400
Net sales/revenue 71.161.100

Fundamental ratios calculated on: 29-05-2020

Ratios
Key figures 29-05-2020
Cash flow
P/C 0,00
   
P/FC 0,00
Balance sheet
ROI-20,75
ROE79,51
Income statement
P/E-35,78
Div. Yield0,00%
P/B0,00
P/S51,80


Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.



DescriptionData
SymbolMOR.DE
Market Capitalization4.104.754.944,00 USD
CountryGermany
IndicesCDAX,HDAX,MDAX,Prime All Share,TecDAX
SectorsHealth service
Raw Data SourceIFRS in Millionen EUR
Stock Split2008-12-23,3.0000/1.0000
Internetwww.morphosys.de


Description of the company

MorphoSys AG, together with its subsidiaries, engages in the research, development, and optimization of therapeutic antibody drug candidates in partnership with pharmaceutical and biotechnology companies. The company, together with its pharmaceutical partners, develops a therapeutic pipeline of approximately 100 drugs for the treatment of cancer, Alzheimer\'s disease, infectious diseases, cardiovascular dysfunction, and inflammation. Its product pipeline includes MOR208, a humanized monoclonal antibody that targets the antigen CD19, which is in Phase III clinical trial for the treatment of B cell malignancies; and MOR202, a human monoclonal HuCAL antibody directed against CD38, which is in Phase II trial for the treatment of multiple myeloma and other cancers. The company\'s product pipeline also comprises MOR103/GSK3196165, a human HuCAL antibody directed against granulocyte-macrophage colony-stimulating factor that is in Phase II clinical trial for treating rheumatoid arthritis and inflammatory hand osteoarthritis. In addition, its product pipeline includes MOR106, a human monoclonal antibody directed against IL-17C, which is in Phase I clinical trial for the treatment of atopic dermatitis; and MOR107 that is in preclinical investigation with a focus on oncology indications. MorphoSys AG has a regional licensing agreement with I-Mab Biopharma to develop and commercialize MOR202 in China, Taiwan, Hong Kong, and Macao. The company was founded in 1992 and is headquartered in Planegg, Germany.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov, www.morphosys.de